Carbylan Therapeutics neurology news

Carbylan reduced headcount by 14 (82%) to three and suspended development of Hydros-TA. Carbylan is

Read the full 156 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE